Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?

por Roccuzzo, Gabriele, Rozzo, Giulia, Burzi, Lorenza, Repetto, Federica, Dapavo, Paolo, Ribero, Simone, Quaglino, Pietro
Publicado 2022